Literature DB >> 15629272

Malignant spinal-cord compression.

Dheerendra Prasad1, David Schiff.   

Abstract

Malignant spinal-cord compression (MSCC) is a common complication of cancer and has a substantial negative effect on quality of life and survival. Despite widespread availability of good diagnostic technology, studies indicate that most patients are diagnosed only after they become unable to walk. We review the epidemiology, pathophysiology, and clinical features of MSCC. Clinical trials have informed the optimum management of MSCC, and we review the role of corticosteroids, radiotherapy, and surgery in the management of patients. We also emphasise advances in radiation delivery and the results of a randomised trial that supported aggressive debulking in patients with MSCC.

Entities:  

Mesh：

Year:  2005        PMID： 15629272     DOI： 10.1016/S1470-2045(04)01709-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


  98 in total

1.  Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial.

Authors:  Xin Shelley Wang; Laurence D Rhines; Almon S Shiu; James N Yang; Ugur Selek; Ibrahima Gning; Ping Liu; Pamela K Allen; Syed S Azeem; Paul D Brown; Hadley J Sharp; David C Weksberg; Charles S Cleeland; Eric L Chang
Journal:  Lancet Oncol       Date:  2012-01-27       Impact factor: 41.316

2.  Metastatic spinal cord compression: a validated survival score for elderly patients.

Authors:  Dirk Rades; Jasmin N Evers; Amira Bajrovic; Theo Veninga; Johann H Karstens; Steven E Schild
Journal:  Strahlenther Onkol       Date:  2014-03-22       Impact factor: 3.621

Review 3.  Top Ten Tips Palliative Care Clinicians Should Know About Spinal Tumors.

Authors:  Theresa Williamson; Brice Painter; Elizabeth P Howell; C Rory Goodwin
Journal:  J Palliat Med       Date:  2018-12-20       Impact factor: 2.947

4.  Reducing kyphotic deformity by posterior vertebral column resection with 360° osteosynthesis in metastatic epidural spinal cord compression (MESCC).

Authors:  Marc Dreimann; Michael Hoffmann; Lennart Viezens; Lukas Weiser; Patrick Czorlich; Sven Oliver Eicker
Journal:  Eur Spine J       Date:  2016-10-11       Impact factor: 3.134

5.  Vertebral lesion distribution in multiple myeloma--assessed by reduced-dose whole-body MDCT.

Authors:  Georg Bier; Christopher Kloth; Christoph Schabel; Malte Bongers; Konstantin Nikolaou; Marius Horger
Journal:  Skeletal Radiol       Date:  2016-01       Impact factor: 2.199

6.  Ovarian Carcinoma With Isolated Spinal Cord Metastasis.

Authors:  Sarah Safadi; Patrick Rendon; Teresa Rutledge; Shadi Mayasy
Journal:  J Investig Med High Impact Case Rep       Date:  2016-07-08

7.  Preoperative prediction for regaining ambulatory ability in paretic non-ambulatory patients with metastatic spinal cord compression.

Authors:  M Ohashi; T Hirano; K Watanabe; K Katsumi; H Shoji; A Sano; H Tashi; I Takahashi; M Wakasugi; Y Shibuya; N Endo
Journal:  Spinal Cord       Date:  2016-10-18       Impact factor: 2.772

8.  Electron beam intraoperative radiotherapy for metastatic epidural spinal cord compression: a prospective observational study.

Authors:  Kei Ito; Shurei Sugita; Yujiro Nakajima; Takahiro Hozumi; Kiyofumi Yamakawa; Masanori Fujiwara; Katsuyuki Karasawa
Journal:  Clin Exp Metastasis       Date:  2021-02-24       Impact factor: 5.150

9.  Development and validation of a prognostic nomogram for the overall survival of patients living with spinal metastases.

Authors:  Xiong-Gang Yang; Jiang-Tao Feng; Feng Wang; Xin He; Hao Zhang; Li Yang; Hao-Ran Zhang; Yong-Cheng Hu
Journal:  J Neurooncol       Date:  2019-09-09       Impact factor: 4.130

10.  A prospective study comparing radiographer- and clinician-based localization for patients with metastatic spinal cord compression (MSCC) to assess the feasibility of a radiographer-led service.

Authors:  Craig Lacey; Clare Ockwell; Imogen Locke; Karen Thomas; Julie Hendry; Helen McNair
Journal:  Br J Radiol       Date:  2015-08-18       Impact factor: 3.039
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.